F5 Inc vs uniQure N.V. Ordinary Shares — how do they compare? F5 Inc trades at $460.11 (market cap $25.89B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: F5 Inc is far larger — about 17.9× uniQure N.V. Ordinary Shares's market cap, and F5 Inc is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| FFIV | QURE | |
|---|---|---|
Market Cap | $25.89B | $1.45B |
Volume | 575,445 | 3,323,243 |
Sector | Technology | Health |
52-Week High | $479.83 | $70.59 |
52-Week Low | $223.99 | $9.03 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | $24.54B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $457.26, down 3.43% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.73 surpassing the $4.00 expectation. Revenue grew to $3.09 billion in 2025, and net income margin improved to 21.95%. Recent news highlights F5's leadership in WAAP platforms and AI security innovations, reinforcing its competitive edge.
The outlook remains positive given earnings momentum and strategic positioning in application security, though valuation multiples like a P/E of 37.95 suggest premium pricing. Risks include competitive pressures and market volatility. Analyst consensus is mixed with a $416.60 price target below the current price, indicating potential near-term caution despite long-term growth prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →